Oxford Immunotec to Present at the Cowen and Company 37th Annual Health Care Conference

 

 

OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the Cowen and Company 37^th Annual Health Care Conference on Monday, March 6, 2017, at 3:20 p.m. EST at the Boston Marriott Copley Place in Boston.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company's first product is the T-SPOT^®.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The company's second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. The T-SPOT.CMV test and the T-SPOT.PRT test are part of the Company's third product line focused on the transplantation market. In addition to these three product lines, the Company has additional active development programs in other immune-regulated conditions. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.

CONTACTS:

For Media Inquiries:
Caroline Crawley 
Oxford Immunotec
Tel: [phone]
[e-mail]

For Investor Inquiries:
Rick Altieri
Chief Financial Officer
Oxford Immunotec
Tel: [phone]
[e-mail]

Mark Klausner
Westwicke Partners
Tel: [phone]
[e-mail]

 

 

---

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire